| 01.07. | SECTOR UPDATE : Health Care Stocks Rebound Late |  |
| 01.07. | SECTOR UPDATE : Health Care Stocks Struggling for Direction | |
| 01.07. | AstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials | |
| 01.07. | AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combination.. | |
| 01.07. | AstraZeneca Enters New 3-Year Agreement with Oxford Biomedica | |
| 01.07. | New chronic kidney disease (CKD) study indicates that CKD is present in one out of ten .. | |
| 01.07. | Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN.. | |
| 01.07. | Pharmaceutical companies still have the upper hand | |
| 01.07. | Oxford BioMedica Extends Agreement With AstraZeneca for Covid-19 Vaccine Facility | |
| 01.07. | Oxford Biomedica signs new deal to make AstraZeneca COVID shot | |
| 01.07. | Oxford Biomedica, AstraZeneca Unit Ink Three-year Deal To Manufacture COVID-19 Vaccines | |
| 01.07. | Oxford Biomedica signs new deal to make AstraZeneca COVID shot | |
| 30.06. | COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregna.. | |
| 30.06. | IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Resp.. | |
| 30.06. | AstraZeneca Says Phase 3 Trial Interim Data Show Imfinzi Plus Chemotherapy Improves Pat.. | |
| 30.06. | ASTRAZENECA : Imfinzi plus chemotherapy significantly improved pathologic complete respons.. | |
| 30.06. | Astrazeneca's Imfinzi Plus Chemotherapy Significantly Improves Pathologic Complete Resp.. | |
| 30.06. | ASTRAZENECA : Imfinzi prometteur dans le cancer du poumon |  |
| 30.06. | S.Korea authorises AstraZeneca COVID therapy Evusheld for vulnerable people | |
| 30.06. | AstraZeneca says Imfinzi combo shows promise in late-stage lung cancer trial | |
| 30.06. | AstraZeneca's Late-stage Lung Cancer Drug Trial Shows Improved Pathologic Complete Resp.. | |
| 30.06. | AstraZeneca Announces Positive High-Level Results from A Planned Interim Analysis of th.. | |
| 30.06. | AstraZeneca Says Imfinzi Improved Pathologic Complete Response in Lung Cancer | |
| 29.06. | European ADRs Move Slightly Higher in Wednesday Trading | |
| 29.06. | FTSE 100 Closes Down 0.2% as Uncertainty Persists | |
| 29.06. | FTSE 100 retreats from two-week high on slowdown worries | |
| 29.06. | Taiwan to receive first doses of Novavax COVID vaccine this week | |
| 29.06. | SK Bioscience Shares Advance on Covid-19 Vaccine Approval | |
| 28.06. | AstraZeneca and Merck - LYNPARZA (olaparib) Receives Positive Opinion From EU CHMP as A.. | |
| 28.06. | Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e.. | |
| 28.06. | Amref and AstraZeneca launch mobile clinics to support last mile COVID-19 vaccination e.. | |
| 27.06. | ASTRAZENECA : l'Enhertu recommandé par le CMUH | |
| 27.06. | European Union Recommends Approval for AstraZeneca and Daiichi Sankyo's Enhertu | |
| 27.06. | Merck, AstraZeneca's Lynparza Obtains EMA's Committee Recommendation as Adjuvant Treatm.. | |
| 27.06. | Enhertu recommended for approval in the EU by CHMP for patients with HER2-positive meta.. | |
| 27.06. | AstraZeneca Pharma India Sets Record Date for Fiscal 2022 Final Dividend | |
| 27.06. | SOUTHWEST ÉCONOMISE, RWE MENACE, ZAL : Planète Bourse du lundi 27 juin | |
| 27.06. | AstraZeneca Partner Daiichi Sankyo Says EMA's Committee Backs Approval of Trastuzumab D.. | |
| 27.06. | ASTRAZENECA : avis favorable du CHMP pour Enhertu | |
| 27.06. | AstraZeneca's Lynparza, Enhertu Win EU Panel's Backing for Approval in Breast Cancer | |
| 27.06. | AstraZeneca PLC Announces Lynparzar Ecommended for Approval in the EU by CHMP as Adjuva.. | |
| 27.06. | Trastuzumab Deruxtecan Recommends for Approval in the EU by CHMP for Patients with HER2.. | |
| 27.06. | AstraZeneca-Daiichi Sankyo Enhertu Breast Cancer Drug Is Recommended for EU Approval | |
| 27.06. | AstraZeneca Lynparza Breast Cancer Treatment Is Recommended for EU Approval | |
| 24.06. | AstraZeneca-Merck & Co's Lynparza Receives EU Panel's Positive Opinion for New Indicati.. | |
| 24.06. | ASTRAZENECA : un nouvel avis positif du CHMP pour le Lynparza | |
| 24.06. | Sanofi, GSK variant-specific COVID shot found effective against Omicron | |
| 23.06. | COVID/VALNEVA : un comité de l'EMA recommande l'autorisation de son vaccin | |
| 23.06. | AstraZeneca Says Health Canada Expands Approved of Breast Cancer Treatment Enhertu | |
| 23.06. | EU watchdog backs Valneva's COVID shot as contract talks go on | |
| 23.06. | ASTRAZENECA : résultats positifs dans la maladie de Wilson | |
| 23.06. | AstraZeneca Drug Candidate to Treat Wilson Disease Meets Primary Endpoint in Phase 3 Tr.. | |
| 23.06. | AstraZeneca's Investigational Drug Meets Primary Endpoint for Wilson Disease | |
| 23.06. | ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Pot.. | |
| 23.06. | ASTRAZENECA : ALXN1840 shows rapid and sustained improvement in copper mobilisation from t.. | |
| 22.06. | ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively | |
| 22.06. | European Medicines Agency Validates AstraZeneca-Daiichi Sankyo Application for Breast C.. | |
| 22.06. | AstraZeneca and Merck - Results From Phase 3 PROpel Trial of LYNPARZA (olaparib) Plus A.. | |
| 22.06. | PROpel Phase III trial positive results of LYNPARZA (olaparib) plus abiraterone in 1st-.. | |
| 22.06. | ASTRAZENECA : l'EMA accepte un dossier dans le cancer du sein | |
| 22.06. | Improved outcome for prostate cancer patients in Phase III PROpel trial | |
| 22.06. | AstraZeneca Partner Daiichi Sankyo Says Type II Variation Application for Breast Cancer.. | |
| 22.06. | COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown | |
| 22.06. | Rode start in Brussel verwacht |  |
| 22.06. | Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tag.. | |
| 22.06. | Biocartis en AstraZeneca breiden samenwerking uit | |
| 22.06. | Biocartis Group NV Announces New Agreement with AstraZeneca for the Development and Mar.. | |
| 22.06. | AstraZeneca-Merck & Co.'s Lynparza Delays Prostate Cancer Progression In Late-stage Stu.. | |
| 21.06. | Merck, AstraZeneca Publish Phase 3 Data for Lynparza-Abiraterone Combo to Treat Prostat.. | |
| 21.06. | European Bourses Close in Green for Second Consecutive Day | |
| 21.06. | ASTRAZENECA : de bons résultats dans le cancer de la prostate | |
| 21.06. | Ionis Pharmaceuticals, AstraZeneca's Eplontersen Meets Primary, Secondary Endpoints in .. | |
| 21.06. | PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st.. | |
| 21.06. | Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTR.. | |
| 21.06. | ASTRAZENECA : résultats encourageants pour l'eplontersen | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
